
    
      Participants who achieved RVR after 4 weeks of PEG-INF alfa-2b plus RBV treatment were
      randomized to receive either 20 or 44 weeks of continued therapy, for a total of 24 or 48
      weeks total of PEG-INF plus RBV therapy.
    
  